Industry Briefs: Mar. 26, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Industry Briefs: Mar. 26, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.


Company News

Corcept Therapeutics has selected PharmaForm as its primary commercial manufacturer for its newly approved drug product, Korlym (mifepristone) for treating Cushing’s syndrome. Read More

Coronado Biosciences has signed a collaboration agreement with Dr. Falk Pharma and OvaMed for the development of trichuris suis ova for treating Crohn’s Disease. Read More

Elite Pharmaceuticals has signed an agreement with a private Hong Kong-based company to develop a branded prescription pharmaceutical product in the US. Read More

GE Healthcare has expanded its Shanghai Fast Trak training center to serve the growing biopharmaceutical industry in China.

Impax and Tolmar have multiproduct agreement for the development, supply, and distribution of alternative dosage-form products. Read More

Marken has completed all commissioning work for its new operational hub in Feltham, United Kingdom. Read More

People News

Adhesives Research appointed Steven Herbert to the position of manufacturing manager.

Albany Molecular Research has named Stephen Rossmeis senior manager to oversee the company's facilities at Burlington, Massachusetts aseptic-fill operations. Read More

Avrio Biopharmaceuticals has appointed William P. Botha as president. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here